Anavex Life Sciences announced preliminary Q2 2026 financial results, highlighting a strategic focus on advancing its lead drug blarcamesine for early Alzheimer's disease, Rett syndrome, and Fragile X syndrome. The company is prioritizing FDA engagement to establish a clear, data-driven regulatory path, with ongoing clinical pharmacology studies in the U.S. and plans to discuss clinical development strategies for its CNS disease programs. Financially, Anavex reported a reduced net loss of $5.3 million for Q2 2026 and a cash balance of $127.4 million, expected to fund operations into mid-to-late 2028. The company also submitted a plan to regain Nasdaq compliance and continues to advance its clinical programs with upcoming milestones expected.
Sanofi has published its half-year financial report for the period ending June 30, 2026, available on its website and filed with regulatory authorities in France and the US. The report highlights Sanofi's strong business performance, including double...
Sanofi has published its financial report for the first half of 2026, available on its website and filed with the French financial authority (AMF). The biopharmaceutical company highlights its innovation in R&D and use of AI to drive long-term growth...
Intercontinental Exchange (ICE) reported strong Q2 2026 results, surpassing analyst expectations with earnings per share of $1.90 versus $1.84 estimated, and revenues of $3.61 billion, well above the $2.63 billion forecast. The company’s growth was d...
First Solar will release its Q2 2026 earnings report on July 30, with analysts expecting earnings per share of $2.90 and revenue of $1.06 billion. The company's large backlog of 47.9 gigawatts valued at $14.40 billion supports strong future sales thr...
Frank Patton and Kimberlee Mott, financial advisors with 45 years of combined experience managing about $150 million in assets, have joined Balmville Wealth Group through LPL Financial. They bring a focus on retirement planning and multigenerational ...
